Global Retinoblastoma Market 2015-2019

Global Retinoblastoma Market 2015-2019

Category : Diagnostic and Biotech
Published On : August  2015
Pages : 95



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About retinoblastoma
Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes. 

Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma. 

Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• Baxter
• Bristol-Myers Squibb
• GlaxoSmithKline
• Spectrum Pharmaceuticals

Other prominent vendors
• BioLineRx 
• Cellceutix
• Icon Bioscience
• Neotropix
• RXi Pharmaceuticals
• Recombio

Key market driver
• Increasing public awareness
• For a full, detailed list, view our report

Key market challenge
• Treatment abandonment
• For a full, detailed list, view our report

Key market trend
• Localized treatment approach
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

01. Executive Summary



02. List of Abbreviations



03. Scope of the Report



03.1 Market Overview



03.2 Product Offerings



04. Market Research Methodology



04.1 Market Research Process



04.2 Research Methodology



05. Introduction



06. Disease Overview



06.1 Understanding the Disease



06.2 Etiology



06.3 Classification



06.3.1 Bilateral Retinoblastoma



06.3.2 Unilateral Retinoblastoma



06.4 Symptoms



06.5 Diagnosis



06.5.1 Patient Examination



06.5.2 Imaging Tests



06.5.3 Biopsy Tests



06.5.4 Clinical Tests



06.6 Epidemiology



06.7 Staging



06.7.1 Intraocular Staging



06.7.2 Extraocular staging



06.8 Management



06.8.1 Cryotherapy



06.8.2 Chemotherapy



06.8.3 Photocoagulation



06.8.4 Radiation therapy



06.8.5 Surgery



06.8.6 Thermo therapy



07. Market Landscape



07.1 Market Overview



07.2 Market Size and Forecast



07.3 Five Forces Analysis



08. Pipeline Analysis



08.1 Key Information of the Pipeline Candidates



08.1.1 NTX-010



08.1.2 Racotumomab



08.1.3 Kevetrin



08.1.4 BL-8040



08.1.5 Melphalan



08.1.6 RNAi Oligonucleotide for Retinoblastoma



09. Market Segmentation by Therapeutic Class of Drugs



09.1 Alkylating Agents



09.2 Antimetabolites



09.3 Microtubule Inhibitors



09.4 Cytotoxic Antibiotics



09.5 Topoisomerase Inhibitors



09.6 Others



10. Market Segmentation by Disease Status



11. Geographical Segmentation



12. Buying Criteria



13. Market Growth Drivers



14. Drivers and their Impact



15. Market Challenges



16. Impact of Drivers and Challenges



17. Market Trends



18. Trends and their Impact



19. Vendor Landscape



19.1 Competitive Scenario



19.1.1 Key News



19.1.2 Mergers and Acquisitions



19.2 Market Share Analysis 2014



19.2.1 Baxter



19.2.2 Bristol-Myers Squibb



19.2.3 GlaxoSmithKline



19.2.4 Spectrum Pharmaceuticals



19.3 Other Prominent Vendors



20. Key Vendor Analysis



20.1 Baxter International Inc.



20.1.1 Key Facts



20.1.2 Business Description



20.1.3 Business Segmentation



20.1.4 Business Strategy



20.1.5 Revenue by Business Segmentation



20.1.6 Revenue by Geographical Segmentation



20.1.7 Key Developments



20.1.8 SWOT Analysis



20.2 Bristol-Myers Squibb



20.2.1 Key Facts



20.2.2 Business Overview



20.2.3 Key Product Offerings



20.2.4 Revenue by Geography



20.2.5 Business Strategy



20.2.6 Key Information



20.2.7 SWOT Analysis



20.3 GlaxoSmithKline



20.3.1 Business Overview



20.3.2 Business Segmentation



20.3.3 Business Segmentation by Revenue 2012 and 2013



20.3.4 Sales by Geography



20.3.5 Key Facts



20.3.6 Pipeline Products



20.3.7 Business Strategy



20.3.8 Key Information



20.3.9 SWOT Analysis



List of Exhibits:

Exhibit 1: Market Research Methodology

Exhibit 2: Classification of Retinoblastoma

Exhibit 3: Symptoms: Percentage Occurrence in Patients

Exhibit 4: Techniques Used for Diagnosing Retinoblastoma

Exhibit 5: Intraocular Staging

Exhibit 6: Extraocular Staging

Exhibit 7: Retinoblastoma: Treatment Options

Exhibit 8: Global Retinoblastoma Market 2014-2019 (US$ million)

Exhibit 9: Pipeline Portfolio

Exhibit 10: Global Retinoblastoma Market by Therapeutic Class of Drugs

Exhibit 11: Global Retinoblastoma Market by Disease Status

Exhibit 12: Global Retinoblastoma Market: Percentage Share of Cases (2014)

Exhibit 13: Global Retinoblastoma Market by Geographical Segmentation 2014

Exhibit 14: Baxter

Exhibit 15: Bristol Myers-Squibb

Exhibit 16: GlaxoSmithKline

Exhibit 17: Spectrum Pharmaceuticals

Exhibit 18: Baxter International Inc. : Business Segmentation

Exhibit 19: Baxter International Inc.: Revenue by Business Segmentation 2013

Exhibit 20: Baxter International Inc.: Revenue by Geographical Segmentation 2013

Exhibit 21: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)

Exhibit 22: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013

Exhibit 23: GlaxoSmithKline: Business Segmentation 2013

Exhibit 24: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)

Exhibit 25: GlaxoSmithKline: Sales by Geography 2013

Exhibit 26: GlaxoSmithKline: Pipeline Products 2013



Enquiry Before Buy